Poseida Therapeutics, Inc. (PSTX) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Kristin Yarema	President, Chief Executive Officer & Director	711,986	1971
Harry J. Leonhardt	General Counsel, Chief Compliance Officer & Corporate Secretary	630,233	1957
Mark J. Gergen	Executive Chairman of the Board	961,797	1963
Kristin Martin	Chief People & Administration Officer	0	N/A
Devon J. Shedlock	Chief Scientific Officer of Cell Therapy	0	N/A
Lisa Portale	Senior Vice President of Regulatory Affairs	0	N/A
Karen Basbaum	Senior Vice President of Business Development	0	N/A
Jeffrey W. Winkelman	Senior Vice President & Chief Patent Counsel	0	N/A
Johanna Mylet	Chief Financial Officer	0	1988
Alexander Chapman	Senior Vice President of Investor Relations & Corporate Communications	0	N/A
Loren Wagner	Chief Operations Officer	0	N/A

Name

Title

Pay

Year Born

Kristin Yarema

President, Chief Executive Officer & Director

711,986

1971

Harry J. Leonhardt

General Counsel, Chief Compliance Officer & Corporate Secretary

630,233

1957

Mark J. Gergen

Executive Chairman of the Board

961,797

1963

Kristin Martin

Chief People & Administration Officer

N/A

Devon J. Shedlock

Chief Scientific Officer of Cell Therapy

N/A

Lisa Portale

Senior Vice President of Regulatory Affairs

N/A

Karen Basbaum

Senior Vice President of Business Development

N/A

Jeffrey W. Winkelman

Senior Vice President & Chief Patent Counsel

N/A

Johanna Mylet

Chief Financial Officer

1988

Alexander Chapman

Senior Vice President of Investor Relations & Corporate Communications

N/A

Loren Wagner

Chief Operations Officer

N/A

Description

Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.